A Nature Medicine article has raised concerns about the use of a placebo control in a phase 3 randomized controlled trial of obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (NMOSD).
The trial, led by L. Wu and colleagues, was published in Nature Medicine in 2026 and evaluated the novel glycoengineered type II anti-CD20 monoclonal antibody in NMOSD patients.
Placebo Control in a Severe Disease
The phase 3 trial by Wu et al. used a placebo-controlled design to assess the safety and efficacy of obinutuzumab β, also known as MIL62.
NMOSD is a severe autoimmune astrocytopathy of the central nervous system driven by pathogenic aquaporin-4-targeted autoantibody immunoglobulin G. Patients face high relapse rates and irreversible neurological disability. Most develop permanent deficits despite current immunotherapies.
Ethical Debate Has History
Ethical debates around placebo-controlled trials in NMOSD are documented. A 2015 article in Multiple Sclerosis and Related Disorders by R. A. Rhodes examined ethical considerations for placebo-controlled relapse prevention treatment trials. M. Levy wrote on the balance of risks the same year.
B. A. C. Cree argued that placebo-controlled trials in NMOSD are both needed and ethical. B. G. Weinshenker and colleagues outlined challenges and opportunities in designing clinical trials for the disease in a 2015 Neurology article.
Established and Emerging Therapies
The trial entered a field with multiple treatments. Previous placebo-controlled trials evaluated inebilizumab (Cree et al., The Lancet, 2019), rituximab (Tahara et al., The Lancet Neurology, 2020), eculizumab (Pittock et al., New England Journal of Medicine, 2019), satralizumab (Yamamura et al., New England Journal of Medicine, 2019; Traboulsee et al., The Lancet Neurology, 2020), and ravulizumab (Pittock et al., Annals of Neurology, 2023).
Long-term effectiveness and safety data for rituximab in NMOSD and MOG antibody disease were reported by Barreras et al. in Neurology (2022).
Obinutuzumab β itself had prior evaluation. A multicenter, single-arm, phase Ib clinical trial by Wu et al. published in Neurology and Therapy (2026) assessed the agent in NMOSD patients before the phase 3 study.
Mechanism and Disease Context
Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass engineered for reduced fucose content, which enhances antibody-dependent cellular cytotoxicity (ADCC) compared to rituximab. It mediates B-cell lysis through immune effector cell engagement, direct activation of intracellular death signaling pathways, and complement cascade activation. The drug is approved for chronic lymphocytic leukemia and follicular lymphoma, per the National Cancer Institute’s formulary.
NMOSD pathology differs fundamentally from multiple sclerosis. Myelin injury in NMOSD is a secondary phenomenon arising from aquaporin-4-IgG-mediated astrocyte destruction. That creates a hostile repair microenvironment marked by disruption of the astrocyte-oligodendrocyte axis, persistent chronic inflammation, and intrinsic oligodendrocyte precursor cell dysfunction.
A 2026 review in Neural Regeneration Research by Yu Yan and colleagues detailed these barriers to myelin repair. They include loss of astrocyte-derived trophic support, sustained proinflammatory cytokines and complement fragments (C3a and C5a) that activate inhibitory signaling pathways, and cell-intrinsic defects in oligodendrocyte precursor cells such as senescence and differentiation arrest.
Nature Medicine, the monthly peer-reviewed journal that published the Wu et al. trial, was established in 1995 by Nature Portfolio to feature research demonstrating novel insight into disease processes with direct evidence of physiological relevance.
It operates without an external editorial board; decisions are made by an in-house team led by editor-in-chief João Monteiro, supported by external peer review. According to Journal Citation Reports, its 2025 impact factor reached 52.5, placing it first among 259 journals in the Biochemistry & Molecular Biology category.
Regulatory and Ethical Framework
The World Medical Association’s Declaration of Helsinki (2024) provides ethical principles for medical research involving human participants, which governs trial design choices such as placebo use. The concerns highlighted in the Nature Medicine article reflect ongoing tension between the need for rigorous efficacy data and the ethical obligation to minimize harm in a rare, debilitating neuroimmune disease where effective treatments already exist.